{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:11:05Z","timestamp":1762377065440,"version":"3.37.3"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004504","name":"Lietuvos Mokslo Taryba","doi-asserted-by":"publisher","award":["SEN\u201009\/2016"],"award-info":[{"award-number":["SEN\u201009\/2016"]}],"id":[{"id":"10.13039\/501100004504","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite novel agents have been introduced to treat castration resistant prostate cancer (CRPC) during the last decade, up to one\u2010third of CRPC patients face primary resistance to new generation compounds. Therefore, sensitive molecular tools are urgently needed for reliable treatment selection and response prediction. This study aimed to evaluate urinary miRNAs and blood circulating androgen receptor (AR) transcript level as a tool for noninvasive outcome prediction for CRPC patients undergoing abiraterone acetate (AA) therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Prostate cancer\u2010specific miR\u2010148a, \u2010365, \u2010375, and \u2010429 were analyzed in 129 urine samples collected from 100 CRPC patients before and during AA therapy via quantitative reverse transcription PCR. To test the prognostic value, urinary miRNA levels alone, as well as combined with AR level were associated with progression\u2010free survival (PFS) and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Level of urinary miR\u2010375 was the highest in CRPC in comparison to noncancerous controls, as well as in combination with miR\u2010429 was predictive for short PFS in AA\u2010treated patients (HR\u2009=\u20092.2, 95% CI: 1.1\u20134.2, <jats:italic>p<\/jats:italic>\u2009=\u20090.023). Especially high prognostic power of all analyzed miRNAs was observed in CRPC cases with high blood AR levels. For PFS prediction a tandem of miR\u2010429 and high AR reached HR of 5.0 (95% CI: 2.2\u201311.8, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), while for prediction of OS the best combination was demonstrated by miR\u2010148a and AR with HR of 3.1 (95% CI: 1.4\u20137.1, <jats:italic>p<\/jats:italic>\u2009=\u20090.006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Urinary miRNAs could be used as prognostic biomarkers for CRPC patients to predict response to AA therapy, especially for the cases with high blood AR levels.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.24293","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T07:13:53Z","timestamp":1640934833000},"page":"475-482","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study"],"prefix":"10.1002","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9766-7108","authenticated-orcid":false,"given":"Kristina","family":"Snipaitiene","sequence":"first","affiliation":[{"name":"Life Sciences Center, Institute of Biomedical Sciences Vilnius University Vilnius Lithuania"},{"name":"National Cancer Institute of Lithuania Vilnius Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3766-5642","authenticated-orcid":false,"given":"Arnas","family":"Bakavicius","sequence":"additional","affiliation":[{"name":"National Cancer Institute of Lithuania Vilnius Lithuania"},{"name":"Urology Centre Vilnius University Vilnius Lithuania"},{"name":"Faculty of Medicine Vilnius University Vilnius Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1338-9575","authenticated-orcid":false,"given":"Juozas R.","family":"Lazutka","sequence":"additional","affiliation":[{"name":"Life Sciences Center, Institute of Biomedical Sciences Vilnius University Vilnius Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6613-0049","authenticated-orcid":false,"given":"Albertas","family":"Ulys","sequence":"additional","affiliation":[{"name":"National Cancer Institute of Lithuania Vilnius Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-3097","authenticated-orcid":false,"given":"Feliksas","family":"Jankevicius","sequence":"additional","affiliation":[{"name":"National Cancer Institute of Lithuania Vilnius Lithuania"},{"name":"Faculty of Medicine Vilnius University Vilnius Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3719-0891","authenticated-orcid":false,"given":"Sonata","family":"Jarmalaite","sequence":"additional","affiliation":[{"name":"Life Sciences Center, Institute of Biomedical Sciences Vilnius University Vilnius Lithuania"},{"name":"National Cancer Institute of Lithuania Vilnius Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.005"},{"key":"e_1_2_11_3_1","first-page":"1","article-title":"Resistance to novel antiandrogen therapies in metastatic castration\u2010resistant prostate cancer","volume":"10","author":"Boudadi K","year":"2016","journal-title":"Clin Med Insights Oncol"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.03.008"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/1008-682X.179159"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.11.038"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015608"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000803"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22572"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14047757"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.147405"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26405"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069239"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.035"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22848"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.233"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29054"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1438"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2020.06.003"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29275"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.50"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57101-7"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa095"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-017-0568-7"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.181"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40719-y"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2010.32"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2810"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.595"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23295"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19124088"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24293","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.24293","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:11:29Z","timestamp":1693195889000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.24293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/pros.24293"],"URL":"https:\/\/doi.org\/10.1002\/pros.24293","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"type":"print","value":"0270-4137"},{"type":"electronic","value":"1097-0045"}],"subject":[],"published":{"date-parts":[[2021,12,30]]},"assertion":[{"value":"2021-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}